6125-48-0

Basic information

• Product Name: 6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyridine-3-carboxamide
• Synonyms: 3-pyridinecarboxamide, 6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-2-thioxo-; 6-Amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyridine-3-carboxamide
• CAS NO: 6125-48-0
• Molecular Formula: C₁₁H₁₀O₃S
• Molecular Weight: 332.3775
• Mol File: 6125-48-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 650.7°C at 760 mmHg
• Flash Point: 347.3°C
• Density: 1.41g/cm³
• Vapor Pressure: 8.19E-17mmHg at 25°C
• Refractive Index: 1.664
• CAS DataBase Reference: 6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyridine-3-carboxamide(6125-48-0)
• EPA Substance Registry System: 6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyridine-3-carboxamide(6125-48-0)

Safety Data

• Hazardous Substances Data: 6125-48-0(Hazardous Substances Data)

Upstream product

• 3528-17-4 2,3-dihydro-4H-[1]benzothiopyran-4-one 
• 17640-15-2 methyl cyanoformate 
• 89-98-5 2-chloro-benzaldehyde 
• 29199-11-9 2-formylthiophenol 
• 55164-16-4 2,2'-dithiodibenzaldehyde 
• 292638-85-8 acrylic acid methyl ester 
• 65924-65-4 2-(tert-butylthio)benzaldehyde 

Downstream Products

• 77606-77-0 2-(4-fluorophenyl)-1,2,3,4-tetrahydro[1]benzothiopyrano[4,3-c]pyrazol-3-one 
• 77606-75-8 2-Phenyl-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 486449-71-2 4-(3-oxo-1,4-dihydro-3H-thiochromeno[4,3-c]pyrazol-2-yl)-benzonitrile 
• 111925-52-1 N-[4-[2-(3,4-dichlorophenyl)ethyl]phenyl]-3,4-dihydro-4-oxo-(2H)-1-benzothiopyran-3-carboxamide-1,1-dioxide 
• 77606-94-1 2-(4-chlorophenyl)-1,2,3,4-tetrahydro[1]benzothiopyrano[4,3-c]pyrazol-3-one-5-oxide 
• 77646-05-0 2-(P-chlorophenyl)-2,3-dihydro<1>benzothiopyrano<4,3-c>pyrazol-3-one 
• 77606-88-3 2-(4-Methanesulfonyl-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77606-92-9 2-Benzyl-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77606-87-2 2-(4-Nitro-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77617-75-5 2-(p-chlorophenyl)-1,2,3,4-tetrahydro<1>benzothiopyrano<4,3-c>pyrazol-3-one 
• 77625-66-2 2-(3,5-Dichloro-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77606-86-1 2-(4-Trifluoromethyl-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77606-84-9 2-(2,4-Dichloro-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 
• 77606-83-8 2-(2,3-Dichloro-phenyl)-1,4-dihydro-2H-thiochromeno[4,3-c]pyrazol-3-one 

Relevant articles and documents

Synthesis and evaluation of antileishmanial and cytotoxic activity of benzothiopyrane derivatives

In continuation of our efforts to identify promising antileishmanial agents based on the chroman scaffold, we synthesized several substituted 2H-thiochroman derivatives, including thiochromenes, thichromanones and hydrazones substituted in C-2 or C-3 with carbonyl or carboxyl groups. Thirty-two compounds were thus obtained, characterized, and evaluated against intracellular amastigotes of Leishmania (V) panamensis. Twelve compounds were active, with EC50 values lower than 40 μM, but only four compounds displayed the highest antileishmanial activity, with EC50 values below 10 μM; these all compounds possess a good Selectivity Index > 2.6. Although two active compounds were thiochromenes, a clear structure-activity relationship was not detected since each active compound has a different substitution pattern.

Novel immunomodulating compounds

The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalisation pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalisation in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalisation determined. There is also described a kit for use in such a method, as well as an immunoregulatory drug capable of blocking down-modulation of a ligand-induced receptor.